Anti-galactan ii monoclonal antibodies targeting klebsiella pneumoniae
AssigneesArsanis Biosciences GmbH, Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
InventorsValeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN
Life of this patent
Estimating the term…
Abstract
A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.
Claims16
1-15. (canceled)
A monoclonal antibody that specifically recognizes Klebsiella pneumoniae serotype O1, which is capable of neutralizing the LPS endotoxin activity, which antibody is selected from any of
- a) an antibody comprising the CDR1-CDR6 sequences of any one of the antibodies listed in Table 1a or Table 1b;
- or
- b) an antibody comprising the the VH and VL sequences of any one of the antibodies depicted in FIG. 2b;
- or
- c) an antibody which is a functionally active variant of a parent antibody that is any one of the antibodies of a) or b), which functionally active variant specifically recognizes Klebsiella pneumoniae serotype O1 and is capable of neutralizing the LPS endotoxin activity, and comprises at least one point mutation in any of the CDR, wherein the number of point mutations is either 0, 1, 2, or 3 point mutations in each of the CDR sequences, wherein the sequence identity in each of the CDR sequences is at least 60% compared to the respective CDR sequences of the parent antibody.
Dependencies are inferred from the claim text.